MetaCap

Addex Therapeutics (ADXN) vs Longeveron (LGVN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Addex Therapeutics is the larger company by market cap ($6.1 million vs $5.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ADXN+10.86%LGVN-31.97%
+75%+13%-49%
Oct 7, 20261 yearNov 20, 2026
ADXN+7.81%LGVN-33.06%
+30%-9%-47%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ADXN versus LGVN key metrics
MetricADXNLGVN
Share price$3.47$1.66
Market cap$6.08M$5.60M
1-day change+2.06%-8.79%
EPS (TTM)$-7.56$-7.95
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$1.20M
Revenue growth (YoY)—-49.87%
Net income (latest FY)—$-22.70M
Gross margin—66.97%
Operating margin—-1942.20%
Net margin—-1893.58%
52-week high$10.43$12.30
52-week low$2.56$1.31
Distance from 52-week high-66.73%-86.50%
Analyst consensus—none
Avg. price target upside—+3589.76%
Average volume383.35K115.35K
Shares outstanding1.75M3.23M
Employees338
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Addex Therapeutics

ADXN stock →

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes.

Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees

About Longeveron

LGVN stock →

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty.

Health Care · Biotechnology: Pharmaceutical Preparations · 38 employees

ADXN vs LGVN FAQ

Which is bigger, Addex Therapeutics or Longeveron?

Addex Therapeutics (ADXN) is larger, with a market capitalization of $6.08M compared with $5.60M for Longeveron (LGVN).

Are Addex Therapeutics and Longeveron in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons